1 or if ten or fewer patients were enrolled or
randomised.
2 Patients were
randomised 1:1 by computerised minimisation algorithm to
3 Patients were
randomised 1:1 to undergo PCI or a placebo procedure by
4 Patients were
randomised (
1:1) using an interactive web response syste
5 e to the nearest NPHC and tribal status, and
randomised (
1:1) within strata.
6 4, 2013, and May 31, 2014, 387 clusters were
randomised (
131 to arm A, 127 to arm B, and 129 to arm C
7 en September 9, 2013, and August 29, 2014, a
randomised 2 x 2 x 3 factorial trial recruited 6- to 23-
8 Among 3,028 women
randomised (
2,990 analysed), 95.6% of 1,498 assigned to
9 open-label 18 mug tiotropium, patients were
randomised (
2:2:1) using a interactive response technolo
10 Participants were
randomised (
3:1) with a block size of four, to receive m
11 were screened, of whom 573 were enrolled and
randomised (
379 to regorafenib and 194 to placebo; popul
12 Patients were
randomised after baseline measure completion, a regular
13 nd Oct 8, 2012, 4884 women were enrolled and
randomised after exclusion of patients at a non-adherent
14 o-treat population that analysed patients by
randomised allocation but excluded patients found inelig
15 iduals from day 10 after vaccination in both
randomised and non-randomised clusters.
16 We included
randomised and quasi-randomised trials, controlled befor
17 These individuals were not
randomised and received neither omalizumab nor oral immu
18 l or ticagrelor during trial conduct was not
randomised and was based on investigator preference.
19 allel three-arm cluster randomised trial was
randomised by household, with 12-mo follow-up, in seven
20 Patients were
randomised centrally and stratified by hospital accordin
21 Patients were stratified according to
randomising centre and serum alpha-fetoprotein concentra
22 re, prospective, open-label, non-inferiority
randomised clinical trial (Sita-Hospital) in five hospit
23 phase 3, two-group, open-label, multicentre,
randomised clinical trial at 92 hospitals in England, Sc
24 ETHODS AND In a cohort study nested within a
randomised clinical trial that compared different treatm
25 designed to improve outcomes were tested in
randomised clinical trials.
26 assigned to immediate vaccination and in non-
randomised clusters received the vaccine immediately; va
27 after vaccination in both randomised and non-
randomised clusters.
28 ws and meta-analysis, we identified studies (
randomised,
cohort, or cross-sectional) by searching MED
29 examined by controlling species richness and
randomising community composition.
30 The
randomised controlled ASTIC trial showed no benefit of m
31 this multicentre, pragmatic, observer-blind,
randomised controlled superiority trial (IMPACT) at 15 N
32 sychosis derived from a previously published
randomised controlled trial (IMPACT).
33 ducted this multicentre, open-label, phase 3
randomised controlled trial (IMvigor211) at 217 academic
34 We did this single-blind,
randomised controlled trial (OASIS) at 26 UK universitie
35 METHODS AND A single-blind, pragmatic
randomised controlled trial (RCT) was conducted at eight
36 Inclusion criteria were: 1)
randomised controlled trial (RCT), quasi-RCT, before-aft
37 We did this single-blind, phase 2,
randomised controlled trial (SUPEREDEN3) at four special
38 We did a cluster
randomised controlled trial among Royal Marines and Army
39 study is, to our knowledge, the first large
randomised controlled trial assessing individual psychol
40 TKIs, and is being investigated in a phase 3
randomised controlled trial comparing lorlatinib to criz
41 A parallel-group
randomised controlled trial design was used.
42 served in the intervention arm of the RHIVA2
randomised controlled trial done in Hackney, London (UK)
43 We did this
randomised controlled trial in 18 SSSs in England.
44 We did a community-based, cluster-
randomised controlled trial in a rural area of North Cen
45 The START trial was a
randomised controlled trial in ART-naive HIV-positive pa
46 , phase 3b/4, head-to-head, non-inferiority,
randomised controlled trial in patients aged 18 years or
47 We conducted a 3-arm, multicentre
randomised controlled trial in primary- and secondary-ca
48 We did a pragmatic, multicentre, open-label,
randomised controlled trial in seven HIV clinics at acad
49 We did a cluster-
randomised controlled trial in two adjoining districts o
50 We did a two-arm
randomised controlled trial in women aged 70-85 years to
51 This multicentre
randomised controlled trial included patients with advan
52 A
randomised controlled trial is needed.
53 ATION: To our knowledge, this is the largest
randomised controlled trial of a psychological intervent
54 To determine the feasibility of conducting a
randomised controlled trial of a specialist physiotherap
55 did a pragmatic, multicentre, parallel-group
randomised controlled trial of adults with bullous pemph
56 Community Health (SEARCH) study is a cluster-
randomised controlled trial of an HIV test-and-treat str
57 nt (INFORM) trial, a pragmatic, multicentre,
randomised controlled trial of patients (>/=18 years) ad
58 METHODS AND We undertook a double-blind
randomised controlled trial of small-quantity lipid-base
59 4907-29) and with the International Standard
Randomised Controlled Trial registry (ISRCTN07742377), a
60 We did a community-level open cluster
randomised controlled trial to compare the effects of a
61 ETATION: To our knowledge, this is the first
randomised controlled trial to document efficacy of a re
62 METHODS AND FINDING: Multicentre, cluster-
randomised controlled trial with raters masked to an onl
63 In this multicentre,
randomised controlled trial, 75 adults with type 1 diabe
64 , superiority, open-label, blinded-endpoint,
randomised controlled trial, patients aged 70 years or y
65 In this cluster-
randomised controlled trial, villages were randomly and
66 this pragmatic, parallel-group, open-label,
randomised controlled trial, we enrolled adults (aged >/
67 s single-centre, open-label, parallel-group,
randomised controlled trial, we enrolled patients aged 1
68 In this unmasked
randomised controlled trial, we randomly assigned (1:1)
69 In this cluster
randomised controlled trial, we recruited non-pregnant a
70 In this
randomised controlled trial, we recruited participants a
71 In this
randomised controlled trial, we recruited patients from
72 y of life using data from an expertise-based
randomised controlled trial.
73 mental disorders has not been assessed in a
randomised controlled trial.
74 We did a prospective, single-site,
randomised controlled trial.
75 ty of high-quality data due to a shortage of
randomised controlled trials (partly because of ethical
76 The findings of
randomised controlled trials (RCT), observational studie
77 Studies were eligible if they were
randomised controlled trials (RCTs) or prospective cohor
78 We performed a meta-analysis of
randomised controlled trials (RCTs) to assess whether in
79 acaftor combination therapy was shown in two
randomised controlled trials (RCTs)-TRAFFIC and TRANSPOR
80 analysis of observational cohort studies and
randomised controlled trials (RCTs).
81 and ISI Web of Science on July 11, 2016, for
randomised controlled trials and observational studies t
82 rictions from inception to Aug 15, 2017, for
randomised controlled trials comparing the use of atraum
83 of individual patient included data from 17
randomised controlled trials done in 14 low-income and m
84 We identified 13
randomised controlled trials done in 739 adults with typ
85 nt of patients receiving AIT and efficacy in
randomised controlled trials for drug development could
86 two pragmatic, parallel-group, multicentre,
randomised controlled trials for our study (PROSPECT [PR
87 h liver cirrhosis, but no adequately powered
randomised controlled trials have been done.
88 We identified 19 relevant
randomised controlled trials of 12 antipsychotic drugs t
89 , PubMed, Biosis, and ClinicalTrials.gov for
randomised controlled trials of antipsychotics for the a
90 However,
randomised controlled trials of diet-related factors hav
91 The INTERACT studies were
randomised controlled trials of early intensive blood pr
92 Emerging
randomised controlled trials of physical activity and di
93 We identified all
randomised controlled trials of systemic therapies in no
94 hasia after stroke, but large-scale, class 1
randomised controlled trials on treatment effectiveness
95 A previous aggregate data meta-analysis of
randomised controlled trials showed that vitamin D suppl
96 We included only
randomised controlled trials that compared fibrinolytic
97 109
randomised controlled trials were eligible for inclusion
98 In blinded
randomised controlled trials, statin therapy has been as
99 lse control disorders have shown efficacy in
randomised controlled trials.
100 four mathematical modelling studies, and no
randomised controlled trials.
101 [PROlapse Surgery: Pragmatic Evaluation and
randomised Controlled Trials]) in 35 centres (a mix of s
102 We initiated this 24 week, open-label,
randomised controlled, comparative effectiveness trial a
103 We did a
randomised controlled, open-label trial with a multi-arm
104 We did a two-arm, cluster-
randomised,
controlled efficacy trial in two districts o
105 In this open-label,
randomised,
controlled phase 3 trial done at two sites i
106 We did a cluster-
randomised,
controlled trial in 12 hospitals in Guangxi,
107 a support the initiation of a multinational,
randomised,
controlled trial of intrathecal HPbetaCD.
108 We did a multicentre, single-blind,
randomised,
controlled trial with follow-up at 4 months
109 n this phase 3, multinational, double-blind,
randomised,
controlled trial, adults (aged 18 years or o
110 For this double-blind, parallel-group,
randomised,
controlled trial, eligible patients had COPD
111 In this
randomised,
controlled, crossover trial, we recruited he
112 LipiDiDiet was a 24-month
randomised,
controlled, double-blind, parallel-group, mu
113 This
randomised,
controlled, double-blind, parallel-group, su
114 METHODS AND This was a parallel-group,
randomised,
controlled, observer-blind trial.
115 In this
randomised,
controlled, open-label, superiority study, w
116 EQoL-MDS was a single-blind,
randomised,
controlled, phase 2 superiority trial of adu
117 s enrolled in the international, open-label,
randomised,
controlled, phase 3 AZURE trial at eligible
118 In this
randomised,
controlled, phase 3 trial, we recruited pati
119 phase 2, non-inferiority, observer-blinded,
randomised,
controlled, single-centre trial in the Domin
120 We did an open-label,
randomised,
controlled, two-arm effectiveness trial at 7
121 In this
randomised,
crossover study, we recruited men and women
122 dose was increased through week 4 until the
randomised dose was achieved, then maintained over 8 wee
123 astatin 10 mg daily or matching placebo in a
randomised double-blind placebo-controlled phase.
124 -label, double-blind phase for 8 weeks and a
randomised,
double-blind phase (parts 1 and 2, reported
125 We did a phase 2,
randomised,
double-blind, active-controlled, non-inferio
126 In this
randomised,
double-blind, active-controlled, phase 3 equ
127 In this international,
randomised,
double-blind, double-dummy, phase 3 trial, w
128 We undertook this
randomised,
double-blind, efficacy, immunogenicity, and
129 We did a
randomised,
double-blind, multicentre phase 2 trial of a
130 This
randomised,
double-blind, multicentre, phase 3 trial was
131 In this
randomised,
double-blind, multicentre, placebo-controlle
132 This
randomised,
double-blind, multiperiod, phase 3 trial was
133 In this phase 3,
randomised,
double-blind, non-inferiority trial, patient
134 In this
randomised,
double-blind, parallel-group, phase 3 trial
135 In this
randomised,
double-blind, phase 2 trial, we recruited pa
136 We did a
randomised,
double-blind, phase 3 trial in patients with
137 In this
randomised,
double-blind, phase 3b trial, we enrolled ad
138 In this
randomised,
double-blind, placebo-controlled phase 2 stu
139 In this multicentre,
randomised,
double-blind, placebo-controlled phase 2 stu
140 In this single-centre,
randomised,
double-blind, placebo-controlled phase 2 tri
141 We did a
randomised,
double-blind, placebo-controlled phase 2b tr
142 We did a
randomised,
double-blind, placebo-controlled pilot trial
143 In this
randomised,
double-blind, placebo-controlled trial at 59
144 Part 1 consisted of a
randomised,
double-blind, placebo-controlled trial done
145 In this multicentre,
randomised,
double-blind, placebo-controlled trial, adul
146 In this single-centre,
randomised,
double-blind, placebo-controlled trial, pati
147 In this
randomised,
double-blind, placebo-controlled trial, we r
148 MP inhibitor doxycyline in a pre-registered,
randomised,
double-blind, placebo-controlled trial.
149 We did a phase 2,
randomised,
double-blind, placebo-controlled, dose-escal
150 The BELLE-2 trial was a
randomised,
double-blind, placebo-controlled, multicentr
151 This was a phase 2,
randomised,
double-blind, placebo-controlled, multicentr
152 In this phase 3,
randomised,
double-blind, placebo-controlled, multicentr
153 We did a phase 3,
randomised,
double-blind, placebo-controlled, multicentr
154 In this
randomised,
double-blind, placebo-controlled, non-inferi
155 In the multicentre,
randomised,
double-blind, placebo-controlled, phase 3 FR
156 This multicentre,
randomised,
double-blind, placebo-controlled, phase 3 st
157 In this
randomised,
double-blind, placebo-controlled, phase 3 tr
158 This
randomised,
double-blind, placebo-controlled, phase 3 tr
159 In this
randomised,
double-blind, placebo-controlled, phase 3 tr
160 RADIANT-4 is a multicentre,
randomised,
double-blind, placebo-controlled, phase 3 tr
161 Patients were eligible for this
randomised,
double-blind, placebo-controlled, phase 3 tr
162 This phase 2,
randomised,
double-blind, placebo-controlled, single-cen
163 In this 1-year,
randomised,
double-blinded, placebo-controlled, phase 3
164 f our small trial in the context of previous
randomised evidence suggest that the benefits of quarter
165 Trial continuation and additional
randomised evidence will be necessary to establish the s
166 SHC as an alternative to routine care in non-
randomised,
exploratory proof-of-concept studies.
167 A
randomised feasibility study was conducted recruiting pa
168 condary analysis of 25 982 patients from the
randomised FOURIER trial, the relationship between achie
169 Analyses were done according to the
randomised FREEDOM treatment assignments.
170 part 2 (weeks 12 and 16 for participants re-
randomised from placebo to tildrakizumab; etanercept was
171 sical activity, or cognitive function across
randomised groups.
172 ccrual before Dec 31, 2010; had to have been
randomised in a way that precluded prior knowledge of tr
173 One patient in the olaparib group was
randomised in error and did not receive study treatment.
174 o onset of diabetes over 160 weeks among all
randomised individuals was 2.7 times longer with liraglu
175 We
randomised mothers 1:1 to receive seasonally recommended
176 This study was part of the non-
randomised,
multi-cohort, open-label, phase 1b KEYNOTE-0
177 Part A of these phase 2,
randomised,
multicentre, open-label, clinical trials enr
178 We did a
randomised,
non-inferiority trial.
179 In this multicentre,
randomised,
open-label phase 2-3 trial, we recruited pat
180 SABRINA is a two-stage,
randomised,
open-label phase 3 study at 113 centres in 3
181 NEMO is an ongoing,
randomised,
open-label phase 3 study done at 118 hospita
182 This was a phase 3,
randomised,
open-label study with a 2 x 2 factorial desi
183 ally enrolled, multicohort, multicentre, non-
randomised,
open-label study, adults (>/=18 years of age
184 This is the final analysis from GATSBY, a
randomised,
open-label, adaptive, phase 2/3 study, done
185 We did an international, prospective,
randomised,
open-label, blinded-endpoint trial in adult
186 In this
randomised,
open-label, international, phase 3 trial, me
187 In this
randomised,
open-label, multicentre, phase 2 trial, 29 a
188 We did a multicentre,
randomised,
open-label, phase 1/2 study of guadecitabine
189 LUNA was a prospective, multicentre,
randomised,
open-label, phase 2 trial of adult patients
190 We did a
randomised,
open-label, phase 3 trial (OAK) in 194 acade
191 CheckMate 141 was a
randomised,
open-label, phase 3 trial in patients with r
192 ACCL0431 was a multicentre,
randomised,
open-label, phase 3 trial that enrolled part
193 In this
randomised,
open-label, phase 3 trial, we recruited pati
194 In this multicentre, international,
randomised,
open-label, phase 3 trial, we recruited pati
195 RESPONSE-2 is a
randomised,
open-label, phase 3b study assessing ruxolit
196 eleration (-0.7, 0, +0.7 m/s(2)) in a pseudo-
randomised order across 4 blocks of 30 trials in both vi
197 We did the multicentre, open-label,
randomised,
parallel, phase 3 SOLE trial in 240 centres
198 DEPICT-1 was a double-blind,
randomised,
parallel-controlled, three-arm, phase 3, mul
199 In the
randomised part of the trial we identified 4539 contacts
200 planning pregnancy, and was assessed in all
randomised participants with baseline assessments.
201 All
randomised patients were included in the time to clinica
202 All
randomised patients with a baseline measurement and at l
203 on the full analysis set, consisting of all
randomised patients, by intention to treat.
204 ion 1.1 in the full analysis population (all
randomised patients, by intention-to-treat).
205 lysed by intention-to-treat in the first 437
randomised patients.
206 A
randomised phase 2 trial of alternative dosing strategie
207 The multicentre, open-label,
randomised phase 3 GOG-0213 trial was done in 67 predomi
208 CLEOPATRA was a
randomised phase 3 study comparing the addition of eithe
209 RETATION: To our knowledge, OAK is the first
randomised phase 3 study to report results of a PD-L1-ta
210 s well as propose a recommended schema for a
randomised phase 3 trial that might potentially answer t
211 lesterolaemia enrolled in an open-label, non-
randomised phase 3 trial.
212 ined patient populations of the three global
randomised phase 3 trials of pirfenidone versus placebo-
213 We did this interim analysis of a non-
randomised,
phase 2 trial at 20 hospitals in the UK.
214 In this open-label, non-
randomised,
phase 2 trial, patients aged 18-55 years, wh
215 Part B of these
randomised,
phase 2, open-label clinical trials enrolled
216 RTC 18071 was a multinational, double-blind,
randomised,
phase 3 trial in patients with stage III cut
217 We did an open-label,
randomised,
phase 3 trial of adult patients (aged >/=18
218 In this multicentre, open-label,
randomised,
phase 3 trial, we recruited patients from 87
219 FOXFIRE, SIRFLOX, and FOXFIRE-Global were
randomised,
phase 3 trials done in hospitals and special
220 In this international, open-label,
randomised,
phase 3, multicentre trial, we enrolled adul
221 In this
randomised,
phase 3, open-label trial, patients were scr
222 a single centre, single-blind, prospective,
randomised pilot trial at the University of Florida Cent
223 This was a multicentre, double-blind,
randomised placebo-controlled trial for which patients w
224 ial was a phase 2 double-blind, multicentre,
randomised placebo-controlled trial in previously untrea
225 In this double-blind
randomised placebo-controlled trial, we enrolled undiagn
226 design was quantified by comparing simulated
randomised placebo-controlled trials within the out-of-s
227 The phase 2, double-blind,
randomised,
placebo-controlled MERIT-1 trial assessed ma
228 We did a double-blind, allocation concealed,
randomised,
placebo-controlled phase 2 trial in two inte
229 In this phase 3, multicentre,
randomised,
placebo-controlled study, we randomly assign
230 pilot safety cohort, we did a double-blind,
randomised,
placebo-controlled trial based in Doneguebou
231 For this double-blind,
randomised,
placebo-controlled trial, we enrolled self-r
232 We report two double-blind,
randomised,
placebo-controlled trials in adults with chr
233 d this single-centre, 150-day, double-blind,
randomised,
placebo-controlled, crossover trial (ReBUILD
234 We did a
randomised,
placebo-controlled, double-blind, crossover
235 In this
randomised,
placebo-controlled, double-blind, phase 2 tr
236 In this double-blind, multicentre,
randomised,
placebo-controlled, phase 3 study (SPIRIT-P2
237 We did a multicentre,
randomised,
placebo-controlled, phase 3 trial (TACE 2) i
238 we searched bibliographic databases for non-
randomised quasi-experimental or observational studies r
239 In this
randomised,
regimen-controlled, double-blind, phase 2 tr
240 Previous
randomised renal denervation studies did not show consis
241 We did an open-label, cluster-
randomised ring vaccination trial (Ebola ca Suffit!) in
242 In this
randomised,
sham-controlled trial, we enrolled adolescen
243 a multicentre, international, single-blind,
randomised,
sham-controlled, proof-of-concept trial.
244 standard high-dose chemotherapy and ongoing
randomised studies will continue to aim to optimise trea
245 tive studies, 20 [37%] were quantitative non-
randomised studies, four [7%] were mixed-methods studies
246 luded from analysis: three were not properly
randomised,
three withdrew from the study, and one was l
247 adverse events (32 in the placebo group, 32
randomised to 200 mg risankizumab, 31 randomised to 600
248 teral subcallosal cingulate white matter and
randomised to 6 months of active or sham DBS, followed b
249 up, 32 randomised to 200 mg risankizumab, 31
randomised to 600 mg risankizumab); 18 had severe advers
250 Participants were
randomised to active (n=12) versus sham (n=13) DBS for 1
251 Those
randomised to additional MT underwent thrombectomy using
252 The novel score was assessed within patients
randomised to different DAPT durations (n=10 081) to ide
253 Patient Health Questionnaire 9 (PHQ-9) were
randomised to either HAP plus enhanced usual care (EUC)
254 fficacy outcome), in patients with acute ICH
randomised to either intensive BP-lowering or standard B
255 month mortality was similar between patients
randomised to intensive BP-lowering treatment and standa
256 n 6 years old, with median CD4% of 12%, were
randomised to monitoring with or without 12-weekly CD4 c
257 ients with stable or responding tumours were
randomised to oral AZD8931 (40 mg twice a day) or placeb
258 ed (n=48) and healthy volunteers (n=48) were
randomised to receive 14 days treatment with 20 mg vorti
259 similar30%-40% of normal G6PD activity) were
randomised to receive 3 d of chloroquine or dihydroartem
260 and no previous regular corticosteroids were
randomised to receive once daily, inhaled budesonide 400
261 Participants were
randomised to the intervention or a treatment as usual c
262 o viral rebound and excluding those who were
randomised to the placebo group) after randomisation.
263 ts were screened and 461 (86%) patients were
randomised to treatment (230 for cariprazine and 231 for
264 se events were reported by 227 (15%) of 1501
randomised treated individuals in the liraglutide group
265 ks was the primary outcome, evaluated in all
randomised treated individuals with at least one post-ba
266 ents who received at least one dose of their
randomised treatment.
267 tients who received at least one dose of the
randomised treatment; the safety analysis was done accor
268 We did this open-label, cluster-
randomised trial (DiRECT) at 49 primary care practices i
269 In this double-blind, multicentre,
randomised trial (GEMINI-ACS-1) done at 371 clinical cen
270 In this multicentre
randomised trial (UK Flexible Sigmoidoscopy Screening Tr
271 stents has not been investigated in a large
randomised trial in an all-comer population.
272 We did a community-based three-arm cluster
randomised trial in healthy children aged 1 month to 5 y
273 In this cluster
randomised trial in northwest Tanzania, eligible village
274 In this multicentre, double-blind,
randomised trial in seven Danish university clinics, we
275 We did an open-label cluster-
randomised trial in villages in the Matlab region of Ban
276 A phase 3
randomised trial is now underway to further assess this
277 We did a phase 4, open-label, cluster
randomised trial of 22 communities in rural KwaZulu-Nata
278 ernational, multicentre, open-label, phase 3
randomised trial of 5102 women with HER2-positive early
279 patients with lymphoma who were treated in a
randomised trial of front-line chemotherapy with cycloph
280 eviously reported ACT II trial was a phase 3
randomised trial of patients of any age with newly diagn
281 ORBITA is a blinded, multicentre
randomised trial of PCI versus a placebo procedure for a
282 matory Thrombosis Outcomes Study (CANTOS), a
randomised trial of the role of interleukin-1beta inhibi
283 DCAST] study is a multicentre, international
randomised trial that enrolled adults older than 60 year
284 METHODS AND A parallel three-arm cluster
randomised trial was randomised by household, with 12-mo
285 In this multicentre, open-label
randomised trial, 102 hospitals (Australia [three], Germ
286 In this cluster-
randomised trial, 68 rural communities (the clusters) in
287 ber, 2015, 55 patients were screened for our
randomised trial, of whom 21 underwent randomisation.
288 In this parallel group, pragmatic,
randomised trial, we recruited whole blood donors aged 1
289 cy of treatments have not been compared in a
randomised trial.
290 ive using data collected alongside a cluster-
randomised trial.
291 dividual patient-level data meta-analysis of
randomised trials done with more than 1000 patients that
292 We identified seven
randomised trials in which 5583 patients were randomly a
293 ison combined these data from two additional
randomised trials of bioresorbable polymer sirolimus-elu
294 n increased risk of falls and fractures, but
randomised trials of vitamin D supplementation have had
295 Data from
randomised trials suggest that maternal multiple micronu
296 We included randomised and quasi-
randomised trials, controlled before-after studies, inte
297 cohort design had higher participation than
randomised trials.
298 and efficacy has not been shown in previous
randomised trials.
299 t the control group and participants not yet
randomised were unaware of their allocation status.
300 uble-blind, multicentre, placebo-controlled,
randomised withdrawal phase 2a trial in 25 secondary car